...a warning about the risk of stress fractures to the label of osteoporosis drug Fosamax alendronate...

...a “developing safety signal” related to a possible association between the company’s osteoporosis drug Fosamax alendronate...

...justices regarding its position that FDA’s rejection of a proposed warning about the company’s Fosamax alendronate...
...arguments, but she will participate in the ruling, according to Supreme Court spokesperson. Steve Usdin Bonalon, Fosamax, alendronate Merck...

...Amgen Shares" ). The resubmission adds data from ARCH, which compared Evenity plus alendronate vs. alendronate...

...Amgen Shares" ). The resubmission adds data from ARCH, which compared Evenity plus alendronate vs. alendronate...

...to include data from the Phase III ARCH study, which compared Evenity plus alendronate vs. alendronate...

...to include data from the Phase III ARCH study, which compared Evenity plus alendronate vs. alendronate...

...of reducing the incidence of new vertebral fractures and clinical fractures at 24 months vs. alendronate...
...ARCH, Evenity also met the secondary endpoint by reducing the incidence of non-vertebral fractures vs. alendronate...
...once-monthly 210 mg subcutaneous Evenity for 12 months followed by alendronate for 12 months or alendronate...

...treatment with Evenity for 12 months followed by alendronate for 12 months vs. treatment with alendronate...

...He said he thinks data from the ongoing Phase III ARCH trial comparing romosozumab to alendronate...